Results 211 to 220 of about 776,039 (330)

Comparative single‐cell transcriptomic profiling of patient‐derived renal carcinoma cells in cellular and animal models of kidney cancer

FEBS Open Bio, EarlyView.
We generated and characterized clear cell renal cell carcinoma models using the patient‐derived RCC243 cell line—including cell culture, orthotopic, and metastatic tumors—via single‐cell RNA‐sequencing for comparisons between models and patient tumor datasets.
Richard Huang, Lynn Kee, Alexander Gont, Jalna Meens, Fraser G. Ferens, Meredith S. Irwin, Laurie Ailles, Scott A. Yuzwa, Claire M. Robinson, Michael Ohh   +9 more
wiley   +1 more source

The evolutionary safety of mutagenic drugs should be assessed before drug approval. [PDF]

PLoS Biol
Lobinska G, Tretyachenko V, Dahan O, Nowak MA, Pilpel Y.   +4 more
europepmc   +1 more source

Predictors of orphan drug approval in the European Union [PDF]

, 2008
Harald E. Heemstra, Remco L. de Vrueh, Sonja van Weely, Hans A. Büller, Hubert G. M. Leufkens   +4 more
openalex   +1 more source

METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response

FEBS Open Bio, EarlyView.
Liver‐specific knockout of N6‐methyladenosine (m6A) methyltransferase METTL3 significantly accelerated hepatic tumor initiation under various oncogenic challenges, contrary to the previously reported oncogenic role of METTL3 in liver cancer cell lines or xenograft models. Mechanistically, METTL3 deficiency reduced m6A deposition on Manf transcripts and
Bo Cui, Silin Tu, Haibo Li, Zhancheng Zeng, Ruiqi Xiao, Jing Guo, Xiaoqi Liang, Chang Liu, Lijie Pan, Wenjie Chen, Mian Ge, Xiaofen Zhong, Linsen Ye, Huaxin Chen, Qi Zhang, Yan Xu   +15 more
wiley   +1 more source

Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs? [PDF]

, 2009
Elizabeth A. Richey, Erica Lyons, Jonathan R. Nebeker, Veena Shankaran, June M. McKoy, Thanh Ha Luu, Narissa J. Nonzee, Steven Trifilio, Oliver Sartor, Al B. Benson, Kenneth R. Carson, Beatrice J. Edwards, Douglas Gilchrist-Scott, Timothy M. Kuzel, Dennis W. Raisch, Martin S. Tallman, Dennis P. West, Steven Hirschfeld, Antonio J Grillo-López, Charles L. Bennett   +19 more
openalex   +1 more source

Soman induces endoplasmic reticulum stress and apoptosis of cerebral organoids via the GRP78‐ATF6‐CHOP signaling pathway

FEBS Open Bio, EarlyView.
Cerebral organoids were employed as a novel model to explore the neurotoxicity of soman. Soman inhibited acetylcholinesterase activity, increased cell apoptosis and upregulated endoplasmic reticulum (ER) stress markers glucose‐regulated protein 78 (GRP78), activating transcription factor 6 (ATF6) and C/EBP homologous protein (CHOP).
Yue Wei, Zhanbiao Liu, Jingjing Shi, Qian Jin, Wenqian Chen, Xuejun Chen, Liqin Li, Hui Chen   +7 more
wiley   +1 more source

Minimum requirements for approval of a drug in status epilepticus [PDF]

, 2009
Michel Baulac, Vincent Navarro
openalex   +1 more source

Co‐expression of HSV‐1 ICP34.5 enhances the expression of gene delivered by self‐amplifying RNA and mitigates its immunogenicity

FEBS Open Bio, EarlyView.
ICP34.5 is one of the most important antihost response proteins. The saRNA‐encoding HSV‐1 neurovirulence protein ICP34.5 clearly mediated the eukaryotic initiation factor 2 alpha subunit (eIF2α) dephosphorylation and significant suppression of innate immune responses in vitro, leading to enhanced expression of the saRNA‐encoded gene.
Xuemin Lu, Yabin Wu, Chunye Zhao, Jie Zheng, Shangwu Chen, Yigang Wang, Yulong Xia   +6 more
wiley   +1 more source

Machine Learning with Statistical Imputation for Predicting Drug Approval

Harvard Data Science Review, 2021
Andrew W. Lo, Kien Wei Siah, Chi Heem Wong   +2 more
doaj   +1 more source

Federal Advisory Committees, Policy Expertise, and the Approval of Drugs and Medical Devices at the FDA [PDF]

, 2010
Stéphane Lavertu, David L. Weimer
openalex   +1 more source